Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2013

01-07-2013 | Original Article

Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT

Authors: N. Schramm, A. Rominger, C. Schmidt, J. N. Morelli, C. Schmid-Tannwald, F. G. Meinel, M. F. Reiser, C. Rist

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2013

Login to get access

Abstract

Purpose

To determine the value of combined 18F-FDG PET/CT with diagnostic contrast-enhanced CT (CECT) in detecting primary malignancies and metastases in patients with paraneoplastic neurological syndromes (PNS) and to compare this with CECT alone.

Methods

PET/CT scans from 66 patients with PNS were retrospectively evaluated. Two blinded readers initially reviewed the CECT portion of each PET/CT scan. In a second session 3 months later, the readers analysed the combined PET/CT scans. Findings on each study were assessed using a four-point-scale (1 normal/benign; 2 inconclusive, further diagnostic work-up may be necessary; 3 malignant; 4 inflammatory). Sensitivity and specificity for malignant findings were calculated for PET/CT and CECT. Interreader agreement was determined by calculating Cohen’s kappa. Pooled data from clinical follow-up (including histopathology and follow-up imaging, median follow-up 20.0 months) served as the reference gold standard.

Results

Both readers classified 12 findings in ten patients (15 %) as malignant on the PET/CT scans (two patients had two primary tumours). One such imaging finding (suspected thymic cancer) was false-positive (i.e. benign histology). The most common tumours were bronchial carcinoma (n = 3), lymph node metastases of gynaecological tumours (n = 3) and tonsillar carcinoma (n = 2). Three of 12 findings (25 %) were not detected by CECT alone (cervical carcinoma, lymph node metastasis and tonsillar carcinoma). In a per-patient analysis, sensitivity and specificity for malignant findings were 100 % and 90 % for PET/CT and 78 % and 88 % for CECT. In 24 % (reader 1) and 21 % (reader 2) of the patients, the PET/CT findings were inconclusive. Of these findings, 57 % (reader 1) and 56 % (reader 2) were only diagnosed with PET (e.g. focal FDG uptake of the thyroid, gastrointestinal tract and ovaries). On follow-up, none of these findings corresponded to malignancy. Overall agreement between the two readers was excellent with a Cohen’s kappa of 0.95 ± 0.04 (p < 0.001) for PET/CT and 0.97 ± 0.03 (p < 0.001) for CECT alone.

Conclusion

In this cohort of patients with PNS, PET/CT exhibited improved detection of underlying malignancy versus CECT alone. While hybrid imaging produces a greater number of inconclusive findings, sensitivity is increased for the detection of head and neck and gynaecological malignancies as well as metastatic lymph node involvement.
Literature
1.
go back to reference World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–5. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–5.
2.
go back to reference Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med. 2004;45 Suppl 1:56S–65S.PubMed Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med. 2004;45 Suppl 1:56S–65S.PubMed
3.
go back to reference Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanché JP, Confavreux C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol. 2000;48:105–8.PubMedCrossRef Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanché JP, Confavreux C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol. 2000;48:105–8.PubMedCrossRef
4.
go back to reference Bannas P, Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol. 2010;20:923–30.PubMedCrossRef Bannas P, Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol. 2010;20:923–30.PubMedCrossRef
5.
go back to reference Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–9.PubMed Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–9.PubMed
6.
go back to reference Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49:17N–21N 37N.PubMedCrossRef Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49:17N–21N 37N.PubMedCrossRef
7.
go back to reference Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157–164.PubMedCrossRef Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157–164.PubMedCrossRef
8.
go back to reference Cashman EC, Macmahon PJ, Shelly MJ, Kavanagh EC. Role of positron emission tomography-computed tomography in head and neck cancer. Ann Otol Rhinol Laryngol. 2011;120:593–602.PubMed Cashman EC, Macmahon PJ, Shelly MJ, Kavanagh EC. Role of positron emission tomography-computed tomography in head and neck cancer. Ann Otol Rhinol Laryngol. 2011;120:593–602.PubMed
9.
go back to reference Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings AJR Am J Roentgenol 1998;170:1513–157.PubMedCrossRef Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings AJR Am J Roentgenol 1998;170:1513–157.PubMedCrossRef
10.
11.
go back to reference Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–54.PubMedCrossRef Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–54.PubMedCrossRef
12.
go back to reference Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, et al. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol. 2005;252:197–201.PubMedCrossRef Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, et al. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol. 2005;252:197–201.PubMedCrossRef
13.
go back to reference Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.PubMedCrossRef Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.PubMedCrossRef
14.
go back to reference Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.PubMedCrossRef Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.PubMedCrossRef
15.
go back to reference Hadjivassiliou M, Alder SJ, Van Beek EJ, Hanney MB, Lorenz E, Rao DG, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand. 2009;119:186–93.PubMedCrossRef Hadjivassiliou M, Alder SJ, Van Beek EJ, Hanney MB, Lorenz E, Rao DG, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand. 2009;119:186–93.PubMedCrossRef
16.
go back to reference Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479–82.PubMedCrossRef Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479–82.PubMedCrossRef
17.
go back to reference Kumar A, Regmi SK, Dutta R, Kumar R, Gupta SD, Das P, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med. 2009;23:569–77.PubMedCrossRef Kumar A, Regmi SK, Dutta R, Kumar R, Gupta SD, Das P, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med. 2009;23:569–77.PubMedCrossRef
18.
go back to reference Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282–6.PubMedCrossRef Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282–6.PubMedCrossRef
19.
go back to reference Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol. 2007;62:328–34.PubMedCrossRef Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol. 2007;62:328–34.PubMedCrossRef
20.
go back to reference Liu RS, Yeh SH, Huang MH, Wang LS, Chu LS, Chang CP, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med. 1995;22:1402–7.PubMedCrossRef Liu RS, Yeh SH, Huang MH, Wang LS, Chu LS, Chang CP, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med. 1995;22:1402–7.PubMedCrossRef
21.
go back to reference Matsuhisa A, Toriihara A, Kubota K, Makino T, Mizusawa H, Shibuya H, et al. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes. Clin Nucl Med. 2012;37:39–43.PubMedCrossRef Matsuhisa A, Toriihara A, Kubota K, Makino T, Mizusawa H, Shibuya H, et al. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes. Clin Nucl Med. 2012;37:39–43.PubMedCrossRef
22.
go back to reference Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR, et al. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008;83:917–22.PubMed Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR, et al. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008;83:917–22.PubMed
23.
go back to reference Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124:2223–31.PubMedCrossRef Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124:2223–31.PubMedCrossRef
24.
go back to reference Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55:713–5.PubMedCrossRef Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55:713–5.PubMedCrossRef
25.
go back to reference Rosenfeld MR, Dalmau J. Update on paraneoplastic neurologic disorders. Oncologist. 2010;15:603–17.PubMedCrossRef Rosenfeld MR, Dalmau J. Update on paraneoplastic neurologic disorders. Oncologist. 2010;15:603–17.PubMedCrossRef
26.
go back to reference Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve. 2000;23:1800–18.PubMedCrossRef Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve. 2000;23:1800–18.PubMedCrossRef
27.
go back to reference Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19–e13.PubMedCrossRef Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19–e13.PubMedCrossRef
28.
go back to reference Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26:4276–81. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26:4276–81.
29.
go back to reference Tsujikawa T, Tsuchida T, Yoshida Y, Kurokawa T, Kiyono Y, Okazawa H, et al. Role of PET/CT in gynecological tumors based on the revised FIGO staging classification. Clin Nucl Med. 2011;36:e114–8.PubMedCrossRef Tsujikawa T, Tsuchida T, Yoshida Y, Kurokawa T, Kiyono Y, Okazawa H, et al. Role of PET/CT in gynecological tumors based on the revised FIGO staging classification. Clin Nucl Med. 2011;36:e114–8.PubMedCrossRef
30.
go back to reference Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682–90.PubMedCrossRef Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682–90.PubMedCrossRef
31.
go back to reference Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1:294–305.PubMedCrossRef Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1:294–305.PubMedCrossRef
32.
go back to reference Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127:2331–8.PubMedCrossRef Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127:2331–8.PubMedCrossRef
Metadata
Title
Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT
Authors
N. Schramm
A. Rominger
C. Schmidt
J. N. Morelli
C. Schmid-Tannwald
F. G. Meinel
M. F. Reiser
C. Rist
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2372-4

Other articles of this Issue 7/2013

European Journal of Nuclear Medicine and Molecular Imaging 7/2013 Go to the issue